Hyperfine Inc Dossier - Source-backed chat

Hyperfine Inc

HYPRNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.29

Intrinsic Value $1.53median of 2 methodsbased on filings through 30 Jun 2026

Market Price $0.87Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 76% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+76%)

Data confidence Sign in to view data confidence

Market Cap $92.4M

Enterprise Value $62.2M

Shares Outstanding 103.7M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Hyperfine, Inc. is leading the democratization of magnetic resonance imaging (MRI) through its Swoop® system, the first FDA-cleared portable, AI-powered point-of-care brain imaging device. The company is demonstrating strong commercial execution with Q1 2026 revenue surging 83% year-over-year and gross margins expanding to 51%. Backed by a bolstered balance sheet with a cash runway extending into 2028, Hyperfine is well-positioned to transition portable MRI from a niche application to mainstream clinical adoption.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.00

Mean target$2.17

High · most bullish analyst$2.50

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.85

The bear case assumes slower hospital adoption due to tight capital budgets, reimbursement hurdles, or competitive pressures from emerging low-field MRI startups. In this scenario, revenue growth slows below 30%, cash burn remains elevated, and the company is forced to seek dilutive equity financing before reaching cash-flow break-even, putting downward pressure on the stock price.

Base CaseCentral scenario

$2.25

The base case assumes continued steady commercial adoption of the Swoop® system in both US and international markets (such as India and Europe). Revenue is expected to meet management's full-year 2026 guidance of $20 million to $22 million, driven by system placements and high-margin recurring service revenues. Gross margins are projected to stabilize in the 50%-55% range, while cash burn remains tightly controlled within the guided $26 million to $28 million.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Redefining brain imaging with the first FDA-cleared portable, AI-powered ultra-low-field MRI system.
Strong top-line momentum with 83% YoY revenue growth in Q1 2026 and significant gross margin expansion to 51%.
Extended cash runway into 2028 supported by a $15 million debt financing in Q1 2026, reducing near-term dilution risk.
Expanding addressable market through international regulatory clearances (CE Mark, UKCA, CDSCO India) and ongoing clinical trials (Contrast PMR).

Key Investment Risks

High cash burn rate relative to current revenue levels, requiring disciplined execution to reach profitability.
Adoption risks associated with hospital capital purchasing cycles and the need for broader clinical validation.
Dependence on a single product platform (Swoop® system) for the majority of future revenues.

Thesis Invalidation Triggers

Failure to meet the full-year 2026 revenue guidance of $20 million to $22 million.
Significant delays in the Contrast PMR clinical trial or a negative regulatory decision from the FDA regarding contrast-agent use expansion.
Annual cash burn exceeding the guided $28 million, accelerating the need for dilutive capital raises.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.